Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, esp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CNS spectrums Ročník 24; číslo S1; s. 38 - 69
Hlavní autoři: Krogmann, Amanda, Peters, Luisa, von Hardenberg, Laura, Bödeker, Katja, Nöhles, Viktor B., Correll, Christoph U.
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York, USA Cambridge University Press 01.08.2019
Témata:
Alzheimer's disease
Amino acids
Anesthesia
Antipsychotics
Cannabidiol
CME Review Article
Dopamine
FDA approval
Headaches
Insomnia
Mental depression
Mortality
Nanocrystals
Narcotics
Nausea
Pathophysiology
Psychosis
Psychotropic drugs
Quality of life
Schizophrenia
Sodium
Treatment resistance
Schizophrenia
antipsychotics
psychopharmacology
randomized controlled trials
phases 2 and 3
ISSN:1092-8529, 2165-6509
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine’s efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
AbstractList Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D 3 antagonist/5-HT 1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D 1 /D 2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal ® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM ® , each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine’s efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine’s efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine's efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine's efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.
Author von Hardenberg, Laura
Krogmann, Amanda
Peters, Luisa
Nöhles, Viktor B.
Bödeker, Katja
Correll, Christoph U.
Author_xml – sequence: 1
  givenname: Amanda
  surname: Krogmann
  fullname: Krogmann, Amanda
  organization: Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
– sequence: 2
  givenname: Luisa
  surname: Peters
  fullname: Peters, Luisa
  organization: Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
– sequence: 3
  givenname: Laura
  surname: von Hardenberg
  fullname: von Hardenberg, Laura
  organization: Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
– sequence: 4
  givenname: Katja
  surname: Bödeker
  fullname: Bödeker, Katja
  organization: Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
– sequence: 5
  givenname: Viktor B.
  surname: Nöhles
  fullname: Nöhles, Viktor B.
  organization: Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
– sequence: 6
  givenname: Christoph U.
  orcidid: 0000-0002-7254-5646
  surname: Correll
  fullname: Correll, Christoph U.
  email: ccorrell@northwell.edu
  organization: Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31482779$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9r1kAQhxep2LfVD-BFFrx4ie7_zXqTYlUseFDBW9hsJm-2JLtxd_OW-ulN6FuEih6GOczz_BhmztBJiAEQek7Ja0qofvOVEsNqyQw1hFAmfjxCO0aVrJQk5gTttnG1zU_RWc7XhAiua_4EnXIqaqa12aH0GWD2YY-XGd_4MuAywFbJzrAU77DtDjY4yNgHnN3gf8V5SBC8fYstTnDwcINjj0M8wIht6DBMkPZb4jzYNFkXx7j3zo4YQvHFQ36KHvd2zPDs2M_R98v33y4-VldfPny6eHdVOUFVqTRruVJCKMmJMj2YTkLLraCU9aKn3PZGkrq3pBVAlbWcEGmclASUNroX_By9usudU_y5QC7N5LODcbQB4pIbxmohFddEr-jLB-h1XFJYt2uYrmsqdU3MSr04Uks7QdfMyU823Tb311wBfQe4FHNO0DfOF1t8DCVZPzaUNNvfmr_-tpr0gXkf_j-HHx07tcl3e_iz9b-t3w2lqGQ
CitedBy_id crossref_primary_10_1016_j_ypsc_2022_03_009
crossref_primary_10_2196_70916
crossref_primary_10_1016_j_neuroimage_2022_119004
crossref_primary_10_1080_13543784_2022_2158811
crossref_primary_10_3892_ijmm_2023_5331
crossref_primary_10_3390_biom15050615
crossref_primary_10_3390_ijms251910668
crossref_primary_10_3389_fpsyt_2021_792019
crossref_primary_10_3390_ph16020175
crossref_primary_10_3390_jpm13030411
crossref_primary_10_3390_ijms24065945
crossref_primary_10_1007_s13346_021_01099_x
crossref_primary_10_1016_j_ajp_2021_102741
crossref_primary_10_1038_s41380_024_02743_x
crossref_primary_10_1007_s40263_022_00935_z
crossref_primary_10_3390_ijms22010409
crossref_primary_10_3390_ijms22052644
crossref_primary_10_1007_s00406_022_01519_0
crossref_primary_10_1111_eip_13200
crossref_primary_10_2147_NDT_S225643
crossref_primary_10_3389_fpsyt_2020_00046
crossref_primary_10_3390_molecules27082550
crossref_primary_10_1097_YIC_0000000000000404
crossref_primary_10_1016_j_biopsych_2019_11_004
crossref_primary_10_3390_ph18050698
crossref_primary_10_3390_ijms252413289
crossref_primary_10_3928_02793695_20200513_01
crossref_primary_10_1093_schbul_sbab062
crossref_primary_10_5498_wjp_v11_i7_277
crossref_primary_10_1016_j_jad_2022_01_004
crossref_primary_10_1016_j_neubiorev_2024_105681
crossref_primary_10_1016_j_schres_2021_11_030
crossref_primary_10_1038_s41386_021_01016_3
crossref_primary_10_1016_j_euroneuro_2022_05_009
crossref_primary_10_1007_s00726_020_02887_4
crossref_primary_10_3389_fpsyt_2021_742058
crossref_primary_10_1007_s12264_021_00740_6
crossref_primary_10_1038_s41537_021_00192_x
crossref_primary_10_1177_20451253211034019
crossref_primary_10_1186_s13063_021_05890_6
crossref_primary_10_1001_jamanetworkopen_2020_24335
crossref_primary_10_1007_s40263_021_00838_5
crossref_primary_10_1016_j_psc_2020_02_008
crossref_primary_10_1080_17460441_2020_1682994
crossref_primary_10_1080_14740338_2024_2396396
crossref_primary_10_1016_j_addr_2021_113912
crossref_primary_10_1016_j_bbr_2021_113507
crossref_primary_10_1093_schizbullopen_sgab013
crossref_primary_10_1080_14656566_2023_2181073
crossref_primary_10_5498_wjp_v11_i12_1228
crossref_primary_10_1007_s40267_022_00931_9
crossref_primary_10_3389_fpsyt_2023_1181758
crossref_primary_10_1016_j_ibneur_2023_03_008
crossref_primary_10_1080_17425247_2024_2374807
crossref_primary_10_3390_ijms23052514
crossref_primary_10_1007_s00115_019_00858_z
crossref_primary_10_1016_j_ejmech_2022_114218
crossref_primary_10_1007_s11055_025_01817_9
crossref_primary_10_3389_fphar_2022_1057083
crossref_primary_10_3389_fpsyt_2021_787097
crossref_primary_10_3389_fphar_2024_1472648
crossref_primary_10_1038_s41398_022_01928_8
crossref_primary_10_1016_j_pbb_2020_172972
crossref_primary_10_1016_j_phrs_2025_107690
crossref_primary_10_1186_s12967_025_06503_5
crossref_primary_10_1016_j_neubiorev_2021_11_032
crossref_primary_10_1007_s40263_025_01216_1
crossref_primary_10_1080_14656566_2023_2228686
crossref_primary_10_1093_ijnp_pyaa026
crossref_primary_10_1111_acps_13359
crossref_primary_10_1002_cpdd_1078
crossref_primary_10_1080_14656566_2022_2145884
crossref_primary_10_1080_14740338_2020_1795126
crossref_primary_10_3390_ph13110365
crossref_primary_10_1007_s11011_023_01271_x
crossref_primary_10_1016_j_euroneuro_2024_01_002
crossref_primary_10_1080_17425255_2022_2147425
crossref_primary_10_1038_s41380_024_02410_1
crossref_primary_10_3389_fpsyt_2025_1606320
crossref_primary_10_1124_jpet_120_000414
Cites_doi 10.1007/s00406-013-0399-y
10.4088/JCP.15032su1
10.1038/nrendo.2011.156
10.1016/S0140-6736(13)60733-3
10.1016/j.schres.2012.07.029
10.4088/JCP.12045tx1c
10.1002/wps.20060
10.1176/appi.ajp.2018.18030280
10.1001/jamapsychiatry.2013.2159
10.1016/j.jclinepi.2013.01.012
10.1002/wps.20516
10.1016/j.molmed.2010.10.010
10.1002/jcph.1387
10.1016/j.bmcl.2009.02.078
10.1007/s00213-014-3704-1
10.2147/TCRM.S117321
10.1001/jamapsychiatry.2013.1292
10.1016/S0140-6736(12)61766-8
10.1186/1471-244X-12-20
10.1038/s41386-019-0355-2
10.1097/JCP.0000000000000479
10.1016/j.schres.2017.10.014
10.1517/14656566.2016.1149164
10.1001/jamapsychiatry.2019.0151
10.1176/appi.ajp.2017.17030325
10.1002/wps.20632
10.3390/ijms18081689
10.1080/14728222.2018.1480723
10.1111/bcp.13246
10.1001/jamapsychiatry.2014.163
10.1016/j.euroneuro.2014.03.008
10.1017/S1092852919000208
10.1016/j.clinthera.2018.09.002
10.1007/s40262-014-0132-7
10.1016/j.schres.2016.03.020
10.1038/npp.2015.176
10.2147/NDT.S197225
10.2174/1381612811319140002
10.1002/wps.20614
10.1007/s13318-018-0488-4
10.1017/S0033291716002245
10.31887/DCNS.2010.12.3/jkane
10.1001/jama.2009.1549
10.1007/s00213-018-4885-9
10.1016/j.schres.2016.07.018
10.3389/fphar.2018.00645
10.4088/JCP.13r08440
10.2147/DDDT.S133205
10.1176/appi.ajp.2016.16050503
10.1038/mp.2011.143
10.1016/j.biopsych.2017.12.006
10.1016/j.biopsych.2016.11.014
10.2174/1871527314666150909113930
10.4088/JCP.12r08064
10.1056/NEJMoa051688
10.1001/jamapsychiatry.2017.0624
10.4088/JCP.10075su1.02
10.1177/0706743717718167
10.1186/1744-859X-11-1
10.4088/JCP.16r10832
10.1124/jpet.114.220194
10.1007/s13318-017-0440-z
10.1017/S1092852914000601
10.1093/schbul/sbs150
10.1016/S0140-6736(12)60239-6
10.1016/S0140-6736(12)61729-2
10.1038/mp.2012.57
10.1017/S003329171600307X
10.1002/wps.20252
10.1097/YCO.0000000000000160
10.4088/JCP.17m11753
10.1080/14737175.2016.1174577
10.1016/S0140-6736(12)61689-4
10.1124/jpet.109.155994
10.1038/npp.2016.20
10.1016/S0140-6736(12)61680-8
10.1176/appi.ajp.2017.16121358
10.1001/archgenpsychiatry.2007.9
10.1093/schbul/sby018.831
10.1038/nature09552
10.1002/wps.20204
10.1002/wps.20309
10.1016/j.biopsych.2015.08.026
10.1002/jcph.141
10.1002/wps.20420
10.4088/JCP.0207e04
10.1517/14728214.2014.958148
10.1176/appi.ajp.2017.17010122
10.3371/CSRP.CI.101118
10.1016/j.biopsych.2018.02.811
10.1016/j.schres.2018.08.028
10.1093/schbul/sbx090
10.1038/nrdp.2015.67
10.1007/s40263-018-0539-z
10.1016/j.psychres.2018.08.079
10.1002/wps.20579
10.1111/ejn.13390
ContentType Journal Article
Copyright Cambridge University Press 2019
Cambridge University Press 2019. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: Cambridge University Press 2019
– notice: Cambridge University Press 2019. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
88G
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
K9.
M0S
M2M
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1017/S109285291900124X
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Psychology Database (Alumni)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Psychology Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList CrossRef
ProQuest One Psychology
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate A. KROGMANN ET AL.
KEEPING UP WITH THE THERAPEUTIC ADVANCES IN SCHIZOPHRENIA
EISSN 2165-6509
EndPage 69
ExternalDocumentID 31482779
10_1017_S109285291900124X
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-E.
.GJ
09C
09E
0E1
0R~
123
29B
36B
53G
5VS
6PF
7X7
8FI
8FJ
AAAZR
AABES
AABWE
AACJH
AAEED
AAGFV
AAKTX
AARAB
AASVR
AAUKB
AAWTL
ABBXD
ABBZL
ABGDZ
ABJNI
ABKKG
ABMYL
ABQTM
ABROB
ABUWG
ABWCF
ABXAU
ABZCX
ABZUI
ACBMC
ACCHT
ACETC
ACGFO
ACGFS
ACIMK
ACQFJ
ACREK
ACUIJ
ACUYZ
ACWGA
ACYZP
ACZBM
ACZUX
ADAZD
ADDNB
ADFEC
ADGEJ
ADKIL
ADOCW
ADOVH
ADOVT
ADVJH
AEBAK
AEBPU
AEHGV
AENCP
AENEX
AENGE
AEPLO
AEYHU
AEYYC
AFFUJ
AFKQG
AFKRA
AFLOS
AFLVW
AFUTZ
AGABE
AGJUD
AGLWM
AGOOT
AHIPN
AHLTW
AHQXX
AHRGI
AIGNW
AIHIV
AIOIP
AISIE
AJCYY
AJPFC
AJQAS
AKZCZ
ALMA_UNASSIGNED_HOLDINGS
ANPSP
AQJOH
ARABE
ARZZG
ATUCA
AUXHV
AYIQA
AZGZS
AZQEC
BBLKV
BCGOX
BENPR
BESQT
BGHMG
BJBOZ
BLZWO
BMAJL
BQFHP
BRIRG
C0O
C1A
C45
CBIIA
CCPQU
CCQAD
CCUQV
CFAFE
CFBFF
CGQII
CHEAL
CJCSC
DC4
DOHLZ
DWQXO
E3Z
EBS
EGQIC
EJD
EMB
EMOBN
F5P
FYUFA
GNUQQ
HG-
HMCUK
HZ~
I.6
I.7
I.9
IH6
IOEEP
IOO
IS6
I~P
JHPGK
JQKCU
JVRFK
KAFGG
KCGVB
KFECR
LHUNA
LW7
M-V
M2M
NIKVX
NZEOI
O9-
OHT
OK1
OVD
P2P
PSYQQ
RCA
ROL
RR0
S6-
S6U
SAAAG
SJN
SV3
SY4
T9M
TEORI
TR2
UKHRP
UT1
UU6
WFFJZ
WXY
ZDLDU
ZJOSE
ZMEZD
ZYDXJ
AATMM
AAXMD
AAYXX
ABVKB
ABVZP
ABXHF
ACDLN
ACRPL
ADNMO
AEMFK
AEMTJ
AFFHD
AFZFC
AGQPQ
AKMAY
CITATION
IPYYG
PHGZM
PHGZT
ALIPV
NPM
3V.
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-c416t-72b36644653069fe9d5eb3a4112f4f13af9508fa0b4e16aa30059c550e6797f43
IEDL.DBID BENPR
ISICitedReferencesCount 97
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000484992900007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1092-8529
IngestDate Thu Oct 02 10:32:33 EDT 2025
Tue Oct 07 07:10:58 EDT 2025
Wed Feb 19 02:31:24 EST 2025
Sat Nov 29 01:31:33 EST 2025
Tue Nov 18 22:08:46 EST 2025
Wed Mar 13 05:52:41 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue S1
Keywords Schizophrenia
antipsychotics
psychopharmacology
randomized controlled trials
phases 2 and 3
Language English
License http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c416t-72b36644653069fe9d5eb3a4112f4f13af9508fa0b4e16aa30059c550e6797f43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7254-5646
OpenAccessLink https://www.cambridge.org/core/services/aop-cambridge-core/content/view/884CF5C0C0BC50E587B1A8B7D69F1E1D/S109285291900124Xa.pdf/div-class-title-keeping-up-with-the-therapeutic-advances-in-schizophrenia-a-review-of-novel-and-emerging-pharmacological-entities-div.pdf
PMID 31482779
PQID 2788157809
PQPubID 5528237
PageCount 32
ParticipantIDs proquest_miscellaneous_2284563707
proquest_journals_2788157809
pubmed_primary_31482779
crossref_citationtrail_10_1017_S109285291900124X
crossref_primary_10_1017_S109285291900124X
cambridge_journals_10_1017_S109285291900124X
PublicationCentury 2000
PublicationDate 20190800
2019-08-00
20190801
PublicationDateYYYYMMDD 2019-08-01
PublicationDate_xml – month: 08
  year: 2019
  text: 20190800
PublicationDecade 2010
PublicationPlace New York, USA
PublicationPlace_xml – name: New York, USA
– name: United States
– name: New York
PublicationTitle CNS spectrums
PublicationTitleAlternate CNS Spectr
PublicationYear 2019
Publisher Cambridge University Press
Publisher_xml – name: Cambridge University Press
References 2010; 12
2017; 83
2017; 82
2013; 66
2017; 47
2010; 468
2019; 59
2019; 15
2017; 45
2019; 204
2019; 18
2014; 24
2013; 70
2018; 84
2018; 40
2011; 17
2018; 44
2012; 12
2018; 43
2012; 11
2016; 36
2016; 79
2016; 77
2018; 175
2013; 19
2013; 18
2018; 9
2017; 74
2015; 40
2013; 12
2019; 24
2013; 53
2017; 78
2011; 72
2016; 41
2008; 65
2014; 19
2012; 379
2010; 2
2009; 19
2018; 32
2007; 68
2016; 46
2018; 79
2014; 53
2017; 62
2015; 1
2015; 12
2012; 141
2015; 14
2005; 353
2018; 269
2012; 380
2009; 331
2017; 174
2013; 382
2013; 263
2016; 17
2014; 40
2018; 22
2016; 16
2016; 15
2011; 8
2018; 17
2015; 28
2018; 195
2017; 16
2015; 232
2017; 13
2015; 352
2013; 74
2018; 235
2019
2016; 176
2017; 18
2018; 12
2014; 71
2016; 174
2009; 302
2019; 176
S109285291900124X_ref40
S109285291900124X_ref41
S109285291900124X_ref42
S109285291900124X_ref44
S109285291900124X_ref45
S109285291900124X_ref46
S109285291900124X_ref47
S109285291900124X_ref48
S109285291900124X_ref49
S109285291900124X_ref50
S109285291900124X_ref51
Kane (S109285291900124X_ref4) 2010; 12
S109285291900124X_ref52
S109285291900124X_ref53
S109285291900124X_ref54
S109285291900124X_ref55
S109285291900124X_ref56
S109285291900124X_ref57
S109285291900124X_ref58
S109285291900124X_ref59
Ibeas Bih (S109285291900124X_ref43) 2015; 12
S109285291900124X_ref20
S109285291900124X_ref21
S109285291900124X_ref8
S109285291900124X_ref9
S109285291900124X_ref22
S109285291900124X_ref5
S109285291900124X_ref23
S109285291900124X_ref24
S109285291900124X_ref6
S109285291900124X_ref7
S109285291900124X_ref25
S109285291900124X_ref26
S109285291900124X_ref27
S109285291900124X_ref1
S109285291900124X_ref2
S109285291900124X_ref28
S109285291900124X_ref3
S109285291900124X_ref29
S109285291900124X_ref30
S109285291900124X_ref31
S109285291900124X_ref32
Patel (S109285291900124X_ref105) 2010; 2
S109285291900124X_ref33
S109285291900124X_ref34
S109285291900124X_ref35
S109285291900124X_ref36
S109285291900124X_ref37
S109285291900124X_ref38
S109285291900124X_ref39
S109285291900124X_ref80
S109285291900124X_ref112
S109285291900124X_ref81
S109285291900124X_ref113
S109285291900124X_ref82
S109285291900124X_ref110
S109285291900124X_ref111
S109285291900124X_ref83
S109285291900124X_ref116
S109285291900124X_ref84
S109285291900124X_ref85
S109285291900124X_ref117
S109285291900124X_ref114
S109285291900124X_ref86
S109285291900124X_ref87
S109285291900124X_ref115
S109285291900124X_ref118
S109285291900124X_ref119
S109285291900124X_ref88
S109285291900124X_ref89
S109285291900124X_ref120
S109285291900124X_ref91
S109285291900124X_ref123
S109285291900124X_ref124
S109285291900124X_ref92
S109285291900124X_ref121
S109285291900124X_ref93
S109285291900124X_ref94
S109285291900124X_ref122
S109285291900124X_ref127
S109285291900124X_ref95
S109285291900124X_ref128
S109285291900124X_ref96
S109285291900124X_ref97
S109285291900124X_ref125
S109285291900124X_ref126
S109285291900124X_ref10
S109285291900124X_ref98
S109285291900124X_ref129
S109285291900124X_ref90
S109285291900124X_ref19
S109285291900124X_ref11
S109285291900124X_ref99
S109285291900124X_ref12
S109285291900124X_ref13
S109285291900124X_ref14
S109285291900124X_ref15
S109285291900124X_ref130
S109285291900124X_ref131
S109285291900124X_ref16
S109285291900124X_ref17
S109285291900124X_ref18
S109285291900124X_ref60
S109285291900124X_ref61
S109285291900124X_ref62
S109285291900124X_ref63
S109285291900124X_ref64
S109285291900124X_ref65
S109285291900124X_ref66
S109285291900124X_ref67
S109285291900124X_ref68
S109285291900124X_ref69
S109285291900124X_ref101
S109285291900124X_ref70
S109285291900124X_ref102
S109285291900124X_ref71
S109285291900124X_ref72
S109285291900124X_ref100
S109285291900124X_ref73
S109285291900124X_ref74
S109285291900124X_ref106
S109285291900124X_ref75
S109285291900124X_ref103
S109285291900124X_ref104
S109285291900124X_ref76
S109285291900124X_ref109
S109285291900124X_ref107
S109285291900124X_ref108
S109285291900124X_ref77
S109285291900124X_ref78
S109285291900124X_ref79
References_xml – volume: 18
  start-page: 1689
  issue: 8
  year: 2017
  article-title: New targets for schizophrenia treatment beyond the dopamine hypothesis
  publication-title: Int J Mol Sci
– volume: 13
  start-page: 757
  year: 2017
  end-page: 777
  article-title: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.
  publication-title: Ther Clin Risk Manag
– volume: 14
  start-page: 119
  issue: 2
  year: 2015
  end-page: 136
  article-title: Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.
  publication-title: World Psychiatry
– volume: 74
  start-page: 603
  issue: 6
  year: 2013
  end-page: 613
  article-title: Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?
  publication-title: J Clin Psychiatry
– volume: 269
  start-page: 271
  year: 2018
  end-page: 277
  article-title: Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: a randomized, double-blind, placebo-controlled trial
  publication-title: Psychiatry Res
– volume: 74
  start-page: e04
  issue: 2
  year: 2013
  article-title: The prevalence of negative symptoms in schizophrenia and their impact on patient functioning and course of illness
  publication-title: J Clin Psychiatry
– volume: 32
  start-page: 605
  issue: 7
  year: 2018
  end-page: 619
  article-title: Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention
  publication-title: CNS Drugs
– volume: 15
  start-page: 1365
  year: 2019
  end-page: 1379
  article-title: Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
  publication-title: Neuropsychiatr Dis Treat
– volume: 380
  start-page: 2129
  issue: 9859
  year: 2012
  end-page: 2143
  article-title: Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
  publication-title: Lancet Lond Engl
– volume: 59
  start-page: 923
  year: 2019
  end-page: 934
  article-title: A review of human studies assessing Cannabidiol’s (CBD) therapeutic actions and potential
  publication-title: J Clin Pharmacol
– volume: 40
  start-page: 1845
  issue: 11
  year: 2018
  end-page: 1854.e2
  article-title: Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia
  publication-title: Clin Ther
– volume: 24
  start-page: 187
  issue: 1
  year: 2019
  end-page: 188
  article-title: 26 A phase 3 study to determine the antipsychotic efficacy and safety of ALKS 3831 in adult patients with acute exacerbation of schizophrenia
  publication-title: CNS Spectr
– volume: 174
  start-page: 927
  issue: 10
  year: 2017
  end-page: 942
  article-title: Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
  publication-title: Am J Psychiatry
– volume: 379
  start-page: 2063
  issue: 9831
  year: 2012
  end-page: 2071
  article-title: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
  publication-title: Lancet Lond Engl
– volume: 43
  start-page: 461
  issue: 4
  year: 2018
  end-page: 469
  article-title: Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil
  publication-title: Eur J Drug Metab Pharmacokinet
– volume: 14
  start-page: 970
  issue: 8
  year: 2015
  end-page: 978
  article-title: Cannabidiol and sodium nitroprusside: two novel neuromodulatory pharmacological interventions to treat and prevent psychosis
  publication-title: CNS Neurol Disord Drug Targets
– volume: 18
  start-page: 543
  issue: 5
  year: 2013
  end-page: 556
  article-title: A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
  publication-title: Mol Psychiatry
– volume: 232
  start-page: 605
  issue: 3
  year: 2015
  end-page: 621
  article-title: Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.
  publication-title: Psychopharmacology (Berl)
– year: 2019
  article-title: Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia
  publication-title: Neuropsychopharmacology
– volume: 65
  start-page: 25
  issue: 1
  year: 2008
  end-page: 27
  article-title: Back to the future: predicting and reshaping the course of psychotic disorder
  publication-title: Arch Gen Psychiatry
– volume: 28
  start-page: 216
  issue: 3
  year: 2015
  end-page: 221
  article-title: Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance
  publication-title: Curr Opin Psychiatry
– volume: 380
  start-page: 2197
  issue: 9859
  year: 2012
  end-page: 2223
  article-title: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.
  publication-title: Lancet Lond Engl
– volume: 53
  start-page: 533
  issue: 6
  year: 2014
  end-page: 543
  article-title: Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment
  publication-title: Clin Pharmacokinet
– volume: 79
  start-page: 952
  issue: 12
  year: 2016
  end-page: 961
  article-title: ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial
  publication-title: Biol Psychiatry
– volume: 16
  start-page: 163
  issue: 2
  year: 2017
  end-page: 180
  article-title: Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
  publication-title: World Psychiatry
– volume: 79
  start-page: 17m11753
  issue: 3
  year: 2018
  article-title: Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial
  publication-title: J Clin Psychiatry
– volume: 8
  start-page: 114
  issue: 2
  year: 2011
  end-page: 126
  article-title: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
  publication-title: Nat Rev Endocrinol
– volume: 84
  start-page: 422
  issue: 6
  year: 2018
  end-page: 432
  article-title: Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial
  publication-title: Biol Psychiatry
– volume: 36
  start-page: 130
  issue: 2
  year: 2016
  end-page: 140
  article-title: Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study
  publication-title: J Clin Psychopharmacol
– volume: 382
  start-page: 951
  issue: 9896
  year: 2013
  end-page: 962
  article-title: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
  publication-title: Lancet Lond Engl
– volume: 331
  start-page: 574
  issue: 2
  year: 2009
  end-page: 590
  article-title: Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
  publication-title: J Pharmacol Exp Ther
– volume: 41
  start-page: 2252
  issue: 9
  year: 2016
  end-page: 2262
  article-title: TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms
  publication-title: Neuropsychopharmacology
– volume: 352
  start-page: 358
  issue: 2
  year: 2015
  end-page: 367
  article-title: A UGT2B10 splicing polymorphism common in African populations may greatly increase drug exposure
  publication-title: J Pharmacol Exp Ther
– volume: 141
  start-page: 144
  issue: 2–3
  year: 2012
  end-page: 152
  article-title: Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day
  publication-title: Schizophr Res
– volume: 12
  start-page: 1215
  year: 2018
  end-page: 1238
  article-title: Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
  publication-title: Drug Des Devel Ther
– volume: 12
  start-page: 216
  issue: 3
  year: 2013
  end-page: 226
  article-title: Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.
  publication-title: World Psychiatry
– volume: 380
  start-page: 2224
  issue: 9859
  year: 2012
  end-page: 2260
  article-title: A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
  publication-title: Lancet
– volume: 78
  start-page: e264
  issue: 3
  year: 2017
  end-page: e278
  article-title: Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis
  publication-title: J Clin Psychiatry
– volume: 17
  start-page: 330
  issue: 3
  year: 2018
  end-page: 340
  article-title: Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
  publication-title: World Psychiatry
– volume: 176
  start-page: 220
  issue: 2–3
  year: 2016
  end-page: 230
  article-title: Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics
  publication-title: Schizophr Res
– volume: 12
  start-page: 130
  issue: 3
  year: 2018
  end-page: 141
  article-title: Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERISTM) for the treatment of schizophrenia
  publication-title: Clin Schizophr Relat Psychoses
– volume: 62
  start-page: 772
  issue: 11
  year: 2017
  end-page: 777
  article-title: Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis
  publication-title: Can J Psychiatry Rev Can Psychiatry
– volume: 16
  start-page: 601
  issue: 6
  year: 2016
  end-page: 614
  article-title: ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
  publication-title: Expert Rev Neurother
– volume: 174
  start-page: 126
  issue: 1–3
  year: 2016
  end-page: 131
  article-title: Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
  publication-title: Schizophr Res
– volume: 9
  start-page: 645
  year: 2018
  article-title: Biochemical and functional characterization of the trace amine-associated receptor 1 (TAAR1) agonist RO5263397
  publication-title: Front Pharmacol
– volume: 17
  start-page: 97
  issue: 2
  year: 2011
  end-page: 107
  article-title: Antipsychotic drugs and obesity
  publication-title: Trends Mol Med
– volume: 24
  start-page: 645
  issue: 5
  year: 2014
  end-page: 692
  article-title: Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
  publication-title: Eur Neuropsychopharmacol
– volume: 15
  start-page: 166
  issue: 2
  year: 2016
  end-page: 174
  article-title: Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.
  publication-title: World Psychiatry
– volume: 74
  start-page: 957
  issue: 10
  year: 2013
  end-page: 965
  article-title: Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies
  publication-title: J Clin Psychiatry
– volume: 83
  start-page: 1476
  issue: 7
  year: 2017
  end-page: 1498
  article-title: Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting atrigel formulation of risperidone: E–R analysis of RBP-7000, a long acting risperidone formulation
  publication-title: Br J Clin Pharmacol
– volume: 468
  start-page: 187
  issue: 7321
  year: 2010
  end-page: 193
  article-title: Rethinking schizophrenia
  publication-title: Nature
– volume: 1
  start-page: 15069
  year: 2015
  article-title: Schizophrenia
  publication-title: Nat Rev Dis Primer
– volume: 46
  start-page: 3443
  issue: 16
  year: 2016
  end-page: 3450
  article-title: The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial
  publication-title: Psychol Med
– volume: 22
  start-page: 513
  issue: 6
  year: 2018
  end-page: 526
  article-title: Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases
  publication-title: Expert Opin Ther Targets
– volume: 70
  start-page: 1267
  issue: 12
  year: 2013
  end-page: 1275
  article-title: Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
  publication-title: JAMA Psychiatry
– volume: 263
  start-page: 367
  issue: 5
  year: 2013
  end-page: 377
  article-title: Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
  publication-title: Eur Arch Psychiatry Clin Neurosci
– volume: 53
  start-page: 1010
  issue: 10
  year: 2013
  end-page: 1019
  article-title: A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone
  publication-title: J Clin Pharmacol
– volume: 19
  start-page: 38
  issue: Suppl 1
  year: 2014
  end-page: 52
  article-title: Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
  publication-title: CNS Spectr
– volume: 77
  start-page: 1
  issue: Suppl 3
  year: 2016
  end-page: 24
  article-title: The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence
  publication-title: J Clin Psychiatry
– volume: 12
  start-page: 20
  issue: 1
  year: 2012
  article-title: A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
  publication-title: BMC Psychiatry
– volume: 14
  start-page: 339
  issue: 3
  year: 2015
  end-page: 347
  article-title: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.
  publication-title: World Psychiatry
– volume: 82
  start-page: 8
  issue: 1
  year: 2017
  end-page: 16
  article-title: Bitopertin in negative symptoms of schizophrenia – results from the phase III FlashLyte and DayLyte studies
  publication-title: Biol Psychiatry
– volume: 18
  start-page: 53
  issue: 1
  year: 2019
  end-page: 66
  article-title: The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials
  publication-title: World Psychiatry
– volume: 40
  start-page: 192
  issue: 1
  year: 2014
  end-page: 213
  article-title: Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials
  publication-title: Schizophr Bull
– volume: 2
  start-page: 85
  year: 2010
  end-page: 90
  article-title: A review on atrigel drug delivery system
  publication-title: J Global Pharma Technol
– volume: 19
  start-page: 2289
  issue: 8
  year: 2009
  end-page: 2294
  article-title: Syntheses of novel high affinity ligands for opioid receptors
  publication-title: Bioorg Med Chem Lett
– volume: 74
  start-page: 675
  issue: 7
  year: 2017
  end-page: 684
  article-title: Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence
  publication-title: JAMA Psychiatry
– volume: 174
  start-page: 1195
  issue: 12
  year: 2017
  end-page: 1202
  article-title: Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia.
  publication-title: Am J Psychiatry
– volume: 195
  start-page: 245
  year: 2018
  end-page: 251
  article-title: A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
  publication-title: Schizophr Res
– volume: 17
  start-page: 921
  issue: 7
  year: 2016
  end-page: 936
  article-title: Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
  publication-title: Expert Opin Pharmacother
– volume: 380
  start-page: 2163
  issue: 9859
  year: 2012
  end-page: 2196
  article-title: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
  publication-title: Lancet Lond Engl
– volume: 174
  start-page: 216
  issue: 3
  year: 2017
  end-page: 229
  article-title: Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology
  publication-title: Am J Psychiatry
– volume: 11
  start-page: 1
  year: 2012
  article-title: Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population
  publication-title: Ann Gen Psychiatry
– volume: 175
  start-page: 225
  issue: 3
  year: 2018
  end-page: 231
  article-title: Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial
  publication-title: Am J Psychiatry
– volume: 12
  start-page: 345
  issue: 3
  year: 2010
  end-page: 357
  article-title: Pharmacologic treatment of schizophrenia
  publication-title: Dialogues Clin Neurosci
– volume: 17
  start-page: 149
  issue: 2
  year: 2018
  end-page: 160
  article-title: What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
  publication-title: World Psychiatry
– volume: 68
  start-page: e04
  issue: 2
  year: 2007
  article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials
  publication-title: J Clin Psychiatry
– volume: 45
  start-page: 2
  issue: 1
  year: 2017
  end-page: 19
  article-title: The dopamine D3 receptor, a quarter century later.
  publication-title: Eur J Neurosci
– volume: 40
  start-page: 3053
  issue: 13
  year: 2015
  end-page: 3060
  article-title: Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia
  publication-title: Neuropsychopharmacology
– volume: 19
  start-page: 2499
  issue: 14
  year: 2013
  end-page: 2511
  article-title: D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy
  publication-title: Curr Pharm Des
– volume: 19
  start-page: 511
  issue: 4
  year: 2014
  end-page: 531
  article-title: Emerging drugs for schizophrenia: an update
  publication-title: Expert Opin Emerg Drugs
– volume: 44
  start-page: 603
  issue: 3
  year: 2018
  end-page: 619
  article-title: Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies
  publication-title: Schizophr Bull
– volume: 12
  start-page: 699
  issue: 4
  year: 2015
  end-page: 730
  article-title: Molecular targets of cannabidiol in neurological disorders
  publication-title: Neurother J Am Soc Exp Neurother
– volume: 72
  start-page: 9
  issue: Suppl 1
  year: 2011
  end-page: 13
  article-title: What are we looking for in new antipsychotics?
  publication-title: J Clin Psychiatry
– volume: 70
  start-page: 668
  issue: 7
  year: 2013
  end-page: 676
  article-title: Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial
  publication-title: JAMA Psychiatry
– volume: 47
  start-page: 981
  issue: 5
  year: 2017
  end-page: 982
  article-title: Letter to the editor: sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
  publication-title: Psychol Med
– volume: 235
  start-page: 1923
  issue: 7
  year: 2018
  end-page: 1932
  article-title: The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
  publication-title: Psychopharmacology (Berl)
– volume: 302
  start-page: 1765
  issue: 16
  year: 2009
  end-page: 1773
  article-title: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
  publication-title: JAMA J Am Med Assoc
– volume: 176
  start-page: 457
  year: 2019
  end-page: 467
  article-title: Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia
  publication-title: Am J Psychiatry
– volume: 71
  start-page: 637
  issue: 6
  year: 2014
  end-page: 646
  article-title: Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
  publication-title: JAMA Psychiatry
– volume: 18
  start-page: 208
  issue: 2
  year: 2019
  end-page: 224
  article-title: Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons
  publication-title: World Psychiatry
– volume: 204
  start-page: 289
  year: 2019
  end-page: 294
  article-title: A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia.
  publication-title: Schizophr Res
– volume: 353
  start-page: 1209
  issue: 12
  year: 2005
  end-page: 1223
  article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
  publication-title: N Engl J Med
– volume: 18
  start-page: 53
  issue: 1
  year: 2013
  end-page: 66
  article-title: Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
  publication-title: Mol Psychiatry
– volume: 43
  start-page: 239
  issue: 2
  year: 2018
  end-page: 249
  article-title: Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study
  publication-title: Eur J Drug Metab Pharmacokinet
– volume: 66
  start-page: S37
  issue: Suppl 8
  year: 2013
  end-page: S41
  article-title: Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry
  publication-title: J Clin Epidemiol
– ident: S109285291900124X_ref84
  doi: 10.1007/s00406-013-0399-y
– ident: S109285291900124X_ref96
  doi: 10.4088/JCP.15032su1
– ident: S109285291900124X_ref118
  doi: 10.1038/nrendo.2011.156
– ident: S109285291900124X_ref120
  doi: 10.1016/S0140-6736(13)60733-3
– ident: S109285291900124X_ref75
  doi: 10.1016/j.schres.2012.07.029
– ident: S109285291900124X_ref79
– ident: S109285291900124X_ref15
  doi: 10.4088/JCP.12045tx1c
– ident: S109285291900124X_ref36
  doi: 10.1002/wps.20060
– ident: S109285291900124X_ref71
– ident: S109285291900124X_ref114
– ident: S109285291900124X_ref125
  doi: 10.1176/appi.ajp.2018.18030280
– ident: S109285291900124X_ref95
  doi: 10.1001/jamapsychiatry.2013.2159
– ident: S109285291900124X_ref41
  doi: 10.1016/j.jclinepi.2013.01.012
– ident: S109285291900124X_ref91
– ident: S109285291900124X_ref68
– ident: S109285291900124X_ref126
– ident: S109285291900124X_ref8
  doi: 10.1002/wps.20516
– ident: S109285291900124X_ref119
  doi: 10.1016/j.molmed.2010.10.010
– ident: S109285291900124X_ref44
  doi: 10.1002/jcph.1387
– ident: S109285291900124X_ref122
  doi: 10.1016/j.bmcl.2009.02.078
– ident: S109285291900124X_ref51
  doi: 10.1007/s00213-014-3704-1
– ident: S109285291900124X_ref22
  doi: 10.2147/TCRM.S117321
– ident: S109285291900124X_ref60
  doi: 10.1001/jamapsychiatry.2013.1292
– ident: S109285291900124X_ref53
– ident: S109285291900124X_ref80
– ident: S109285291900124X_ref11
  doi: 10.1016/S0140-6736(12)61766-8
– ident: S109285291900124X_ref2
  doi: 10.1186/1471-244X-12-20
– ident: S109285291900124X_ref48
  doi: 10.1038/s41386-019-0355-2
– ident: S109285291900124X_ref109
  doi: 10.1097/JCP.0000000000000479
– ident: S109285291900124X_ref123
  doi: 10.1016/j.schres.2017.10.014
– ident: S109285291900124X_ref74
– ident: S109285291900124X_ref111
– ident: S109285291900124X_ref129
– ident: S109285291900124X_ref92
– ident: S109285291900124X_ref34
  doi: 10.1517/14656566.2016.1149164
– ident: S109285291900124X_ref86
– ident: S109285291900124X_ref63
  doi: 10.1001/jamapsychiatry.2019.0151
– ident: S109285291900124X_ref46
  doi: 10.1176/appi.ajp.2017.17030325
– ident: S109285291900124X_ref102
– ident: S109285291900124X_ref9
  doi: 10.1002/wps.20632
– ident: S109285291900124X_ref33
  doi: 10.3390/ijms18081689
– ident: S109285291900124X_ref65
  doi: 10.1080/14728222.2018.1480723
– ident: S109285291900124X_ref58
– ident: S109285291900124X_ref110
  doi: 10.1111/bcp.13246
– ident: S109285291900124X_ref72
  doi: 10.1001/jamapsychiatry.2014.163
– ident: S109285291900124X_ref19
  doi: 10.1016/j.euroneuro.2014.03.008
– ident: S109285291900124X_ref128
  doi: 10.1017/S1092852919000208
– ident: S109285291900124X_ref124
  doi: 10.1016/j.clinthera.2018.09.002
– ident: S109285291900124X_ref107
  doi: 10.1007/s40262-014-0132-7
– ident: S109285291900124X_ref108
  doi: 10.1016/j.schres.2016.03.020
– ident: S109285291900124X_ref83
  doi: 10.1038/npp.2015.176
– ident: S109285291900124X_ref101
  doi: 10.2147/NDT.S197225
– ident: S109285291900124X_ref97
– ident: S109285291900124X_ref81
  doi: 10.2174/1381612811319140002
– ident: S109285291900124X_ref113
– ident: S109285291900124X_ref26
  doi: 10.1002/wps.20614
– ident: S109285291900124X_ref99
  doi: 10.1007/s13318-018-0488-4
– ident: S109285291900124X_ref127
– ident: S109285291900124X_ref90
– ident: S109285291900124X_ref62
  doi: 10.1017/S0033291716002245
– volume: 12
  start-page: 345
  year: 2010
  ident: S109285291900124X_ref4
  article-title: Pharmacologic treatment of schizophrenia
  publication-title: Dialogues Clin Neurosci
  doi: 10.31887/DCNS.2010.12.3/jkane
– ident: S109285291900124X_ref117
  doi: 10.1001/jama.2009.1549
– ident: S109285291900124X_ref88
  doi: 10.1007/s00213-018-4885-9
– ident: S109285291900124X_ref38
  doi: 10.1016/j.schres.2016.07.018
– ident: S109285291900124X_ref69
  doi: 10.3389/fphar.2018.00645
– ident: S109285291900124X_ref40
  doi: 10.4088/JCP.13r08440
– ident: S109285291900124X_ref116
  doi: 10.2147/DDDT.S133205
– ident: S109285291900124X_ref98
– ident: S109285291900124X_ref32
  doi: 10.1176/appi.ajp.2016.16050503
– ident: S109285291900124X_ref7
  doi: 10.1038/mp.2011.143
– ident: S109285291900124X_ref94
  doi: 10.1016/j.biopsych.2017.12.006
– ident: S109285291900124X_ref73
  doi: 10.1016/j.biopsych.2016.11.014
– ident: S109285291900124X_ref59
  doi: 10.2174/1871527314666150909113930
– ident: S109285291900124X_ref30
  doi: 10.4088/JCP.12r08064
– ident: S109285291900124X_ref121
  doi: 10.1056/NEJMoa051688
– ident: S109285291900124X_ref21
  doi: 10.1001/jamapsychiatry.2017.0624
– ident: S109285291900124X_ref130
  doi: 10.4088/JCP.10075su1.02
– ident: S109285291900124X_ref31
  doi: 10.1177/0706743717718167
– ident: S109285291900124X_ref89
– ident: S109285291900124X_ref18
  doi: 10.1186/1744-859X-11-1
– ident: S109285291900124X_ref25
  doi: 10.4088/JCP.16r10832
– ident: S109285291900124X_ref70
  doi: 10.1124/jpet.114.220194
– ident: S109285291900124X_ref85
  doi: 10.1007/s13318-017-0440-z
– ident: S109285291900124X_ref20
  doi: 10.1017/S1092852914000601
– ident: S109285291900124X_ref42
  doi: 10.1093/schbul/sbs150
– ident: S109285291900124X_ref6
  doi: 10.1016/S0140-6736(12)60239-6
– ident: S109285291900124X_ref13
  doi: 10.1016/S0140-6736(12)61729-2
– ident: S109285291900124X_ref66
  doi: 10.1038/mp.2012.57
– ident: S109285291900124X_ref64
  doi: 10.1017/S003329171600307X
– ident: S109285291900124X_ref29
  doi: 10.1002/wps.20252
– ident: S109285291900124X_ref39
  doi: 10.1097/YCO.0000000000000160
– ident: S109285291900124X_ref77
  doi: 10.4088/JCP.17m11753
– ident: S109285291900124X_ref49
  doi: 10.1080/14737175.2016.1174577
– ident: S109285291900124X_ref12
  doi: 10.1016/S0140-6736(12)61689-4
– ident: S109285291900124X_ref55
  doi: 10.1124/jpet.109.155994
– ident: S109285291900124X_ref56
  doi: 10.1038/npp.2016.20
– ident: S109285291900124X_ref14
  doi: 10.1016/S0140-6736(12)61680-8
– ident: S109285291900124X_ref115
– ident: S109285291900124X_ref131
– ident: S109285291900124X_ref67
– ident: S109285291900124X_ref5
  doi: 10.1176/appi.ajp.2017.16121358
– ident: S109285291900124X_ref17
  doi: 10.1001/archgenpsychiatry.2007.9
– ident: S109285291900124X_ref50
  doi: 10.1093/schbul/sby018.831
– ident: S109285291900124X_ref16
  doi: 10.1038/nature09552
– ident: S109285291900124X_ref82
– ident: S109285291900124X_ref23
  doi: 10.1002/wps.20204
– ident: S109285291900124X_ref28
  doi: 10.1002/wps.20309
– ident: S109285291900124X_ref52
  doi: 10.1016/j.biopsych.2015.08.026
– ident: S109285291900124X_ref54
– ident: S109285291900124X_ref106
  doi: 10.1002/jcph.141
– ident: S109285291900124X_ref27
  doi: 10.1002/wps.20420
– ident: S109285291900124X_ref10
  doi: 10.4088/JCP.0207e04
– ident: S109285291900124X_ref35
  doi: 10.1517/14728214.2014.958148
– ident: S109285291900124X_ref78
  doi: 10.1176/appi.ajp.2017.17010122
– ident: S109285291900124X_ref112
– ident: S109285291900124X_ref104
  doi: 10.3371/CSRP.CI.101118
– ident: S109285291900124X_ref3
– ident: S109285291900124X_ref87
– ident: S109285291900124X_ref100
  doi: 10.1016/j.biopsych.2018.02.811
– ident: S109285291900124X_ref93
– ident: S109285291900124X_ref57
  doi: 10.1016/j.schres.2018.08.028
– volume: 2
  start-page: 85
  year: 2010
  ident: S109285291900124X_ref105
  article-title: A review on atrigel drug delivery system
  publication-title: J Global Pharma Technol
– ident: S109285291900124X_ref37
  doi: 10.1093/schbul/sbx090
– ident: S109285291900124X_ref1
  doi: 10.1038/nrdp.2015.67
– ident: S109285291900124X_ref103
– ident: S109285291900124X_ref76
– volume: 12
  start-page: 699
  year: 2015
  ident: S109285291900124X_ref43
  article-title: Molecular targets of cannabidiol in neurological disorders
  publication-title: Neurother J Am Soc Exp Neurother
– ident: S109285291900124X_ref45
  doi: 10.1007/s40263-018-0539-z
– ident: S109285291900124X_ref61
  doi: 10.1016/j.psychres.2018.08.079
– ident: S109285291900124X_ref24
  doi: 10.1002/wps.20579
– ident: S109285291900124X_ref47
  doi: 10.1111/ejn.13390
SSID ssj0043783
Score 2.5358846
SecondaryResourceType review_article
Snippet Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly...
SourceID proquest
pubmed
crossref
cambridge
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 38
SubjectTerms Alzheimer's disease
Amino acids
Anesthesia
Antipsychotics
Cannabidiol
CME Review Article
Dopamine
FDA approval
Headaches
Insomnia
Mental depression
Mortality
Nanocrystals
Narcotics
Nausea
Pathophysiology
Psychosis
Psychotropic drugs
Quality of life
Schizophrenia
Sodium
Treatment resistance
Title Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
URI https://www.cambridge.org/core/product/identifier/S109285291900124X/type/journal_article
https://www.ncbi.nlm.nih.gov/pubmed/31482779
https://www.proquest.com/docview/2788157809
https://www.proquest.com/docview/2284563707
Volume 24
WOSCitedRecordID wos000484992900007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2165-6509
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0043783
  issn: 1092-8529
  databaseCode: 7X7
  dateStart: 20120601
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2165-6509
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0043783
  issn: 1092-8529
  databaseCode: BENPR
  dateStart: 20120601
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Psychology Database
  customDbUrl:
  eissn: 2165-6509
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0043783
  issn: 1092-8529
  databaseCode: M2M
  dateStart: 20120601
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/psychology
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB-8PRFf_D5dPY8RfBKL3SZtGl9E5Q5BdzlEYd-WJE3g4GjX7e79_c606e6KuC--FNombWA-k5n5DcBrX7o882aSkO00iTSTMrE6LxMXrJVOWvIwOsj8b2o2K-dzfRkP3NqYVjnoxE5RV43jM_J3GeOeE3ul-sPyV8Jdozi6GltoHMExI5XJERx_Op9dfh90sRSq7FPsNcl9nukhrsmg0fyQn5FJJC0t5_voCn9aqX-4np0Jurj_v4t_APei84kfe255CLd8_QjuTGN4_TGsvnrP9VO4WSIf0CJ5h7hXoYUxY6DFqxrb_XS992iwr4LBJmDd3PhrNHWFXH7MbZBwuYPIZrbAAcv1Cfy8OP_x-UsSmzIkjny3daIyK4qig2VLCx28rnLajxtJfluQYSJM4L6ywaRW-klhDMPha0f7IF8orYIUJzCqm9o_AxRlCErYVOSVlbQ1skFmLtdVWthUem3H8HZLkEUUrXbRp6WpxV_0G0M60GzhIsA599m4PjTlzXbKskf3ODT4dCDubjU7yo7h1fY1iSjHXUztmw2NIRcgL4RK1Rie9gy0_ZvocFiVfn744y_gLnlqus88PIXRerXxL-G2u1lftaszOFJz1V3LsygBdDfNpr8BV2YIpQ
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoBLeZctBQYJLoiIbOzEMVKFEFC12u2KQ5H2FmzHlipVyXazW8Sf4jcyzmu3QuytB66O47w-z3yOZ74BeG1TE0dWDQPynSrgapgGWsZpYJzW3HBNDKOWzB-LySSdTuW3Lfjd5cL4sMrOJtaGOi-N_0f-PvK65wSvUH6cXQS-apTfXe1KaDSwGNlfP2nJVh0cf6Hv-yaKDr-efj4K2qoCgSHysQhEpFmS1LpiYSKdlXlMC0rFiXg47oZMOV8Y1alQcztMlPJ67tIQkbeJkMJxRuPegJtkx4UPIRPTfoHHmUibgH5JViaOZLeL6iWqfaNvIwdMPoFP17UcrvrEfxDd2uEd3vvfXtV92GmpNX5q5sID2LLFQ7h90gYPPIL5yFqfHYbLGfrfz0jcF9fyz7CNh6jwrMBqPRjxAypscnywdFiUl_YcVZGjT672RZ5wthIA96DHTqn2MXy_lid-AttFWdingCx1TjAdsjjXnBZ-2vHIxDIPEx1yK_UA3vUAyFrDUWVN0J3I_sLLAMIOI5lp5dt9FZHzTae87U-ZNdolmzrvd2Ba3c0KSQN41R8mA-R3lVRhyyX1IYITJ0yEYgC7DWD7q7FaZVbIvc2Dv4Q7R6cn42x8PBk9g7vESWUTY7kP24v50j6HW-ZycVbNX9TzDeHHdaP2DysdXuY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VgiouLa9CaIFBggti1c3au15XqhCiRFRpoh5Aym2xvbZUqdoN2aQVf41fx3gfSRAitx64er3vzzOf7ZlvAN7Y1MSRVf2AfKcKuOqngZZxGhinNTdcE8OoJfPPxXicTibyYgt-dbkwPqyys4m1oc5L49fIjyKve07wCuWRa8MiLk4HH6Y_Al9Byu-0duU0GogM7c8bmr5VJ2en9K_fRtHg89dPX4K2wkBgiIjMAxFpliS1xliYSGdlHtPkUnEiIY67PlPOF0l1KtTc9hOlvLa7NETqbSKkcJzRde_AXcHj2FdPGEWjzgtwJtImuF-SxYkj2e2oerlq3-jbyBmTf-CTdV2HP_3jP0hv7fwGe__zZ3sAuy3lxo_NGHkIW7Z4BDujNqjgMcyG1vqsMVxM0S9LI3FiXMtLwzZOosLLAqv1IMVjVNjk_mDpsCiv7RWqIkefdO2LP-F0JQzuBwN2CrZP4NutvPE-bBdlYZ8BstQ5wXTI4lxzmhBqxyMTyzxMdMit1D14vwRD1hqUKmuC8UT2F3Z6EHZ4yUwr6-6ri1xtOuXd8pRpo2myqfNhB6zV06xQ1YPXy8NkmPxukypsuaA-RHzihIlQ9OBpA97l3VitPivk880XfwU7BNbs_Gw8PID7RFVlE3p5CNvz2cK-gHvmen5ZzV7WQw_h-22D9jcwAWep
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Keeping+up+with+the+therapeutic+advances+in+schizophrenia%3A+a+review+of+novel+and+emerging+pharmacological+entities&rft.jtitle=CNS+spectrums&rft.au=Krogmann%2C+Amanda&rft.au=Peters%2C+Luisa&rft.au=von+Hardenberg%2C+Laura&rft.au=B%C3%B6deker%2C+Katja&rft.date=2019-08-01&rft.pub=Cambridge+University+Press&rft.issn=1092-8529&rft.eissn=2165-6509&rft.volume=24&rft.issue=S1&rft.spage=38&rft.epage=69&rft_id=info:doi/10.1017%2FS109285291900124X&rft.externalDocID=10_1017_S109285291900124X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1092-8529&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1092-8529&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1092-8529&client=summon